KR102430892B1 - 비강 울혈을 치료/예방하기 위한 카르복실산 - Google Patents

비강 울혈을 치료/예방하기 위한 카르복실산 Download PDF

Info

Publication number
KR102430892B1
KR102430892B1 KR1020187033155A KR20187033155A KR102430892B1 KR 102430892 B1 KR102430892 B1 KR 102430892B1 KR 1020187033155 A KR1020187033155 A KR 1020187033155A KR 20187033155 A KR20187033155 A KR 20187033155A KR 102430892 B1 KR102430892 B1 KR 102430892B1
Authority
KR
South Korea
Prior art keywords
solution
nasal congestion
pharmaceutical composition
hours
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187033155A
Other languages
English (en)
Korean (ko)
Other versions
KR20190009294A (ko
Inventor
베티나 에른스트
Original Assignee
프로포넌트 바이오테크 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로포넌트 바이오테크 게엠베하 filed Critical 프로포넌트 바이오테크 게엠베하
Publication of KR20190009294A publication Critical patent/KR20190009294A/ko
Application granted granted Critical
Publication of KR102430892B1 publication Critical patent/KR102430892B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187033155A 2016-05-17 2017-05-17 비강 울혈을 치료/예방하기 위한 카르복실산 Active KR102430892B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16169882.4 2016-05-17
EP16169882 2016-05-17
PCT/EP2017/061832 WO2017198702A1 (en) 2016-05-17 2017-05-17 Carboxylic acid for treating/preventing nasal congestion

Publications (2)

Publication Number Publication Date
KR20190009294A KR20190009294A (ko) 2019-01-28
KR102430892B1 true KR102430892B1 (ko) 2022-08-09

Family

ID=56014856

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033155A Active KR102430892B1 (ko) 2016-05-17 2017-05-17 비강 울혈을 치료/예방하기 위한 카르복실산

Country Status (13)

Country Link
US (1) US20200000751A1 (enExample)
EP (1) EP3458043A1 (enExample)
JP (1) JP6975473B2 (enExample)
KR (1) KR102430892B1 (enExample)
CN (1) CN109152754A (enExample)
AU (1) AU2017266726A1 (enExample)
BR (1) BR112018072177A2 (enExample)
CA (1) CA3020485A1 (enExample)
CL (1) CL2018003270A1 (enExample)
MX (1) MX2018013475A (enExample)
RU (1) RU2018143564A (enExample)
SG (2) SG10202006016QA (enExample)
WO (1) WO2017198702A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11206245B2 (en) * 2009-10-14 2021-12-21 Trice Imaging, Inc. Systems and devices for encrypting, converting and interacting with medical images
US11948678B2 (en) * 2009-10-14 2024-04-02 Trice Imaging, Inc. Systems and devices for encrypting, converting and interacting with medical images
GB202004690D0 (en) * 2020-03-31 2020-05-13 Edinburgh Napier Univ Composition for enhancing immune response of cells
US12414928B2 (en) 2021-05-14 2025-09-16 Rene Dumalaog Javier Viral inactivation spray and gargling formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
WO2014053592A1 (en) * 2012-10-03 2014-04-10 Proponent Biotech Gmbh Esters of short chains fatty acids for use in the treatment of immunogenic disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063363A (en) * 1997-05-27 2000-05-16 Goodwin; Gary J Treatment for upper respiratory tract infections with potassium salts
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
EP1671629A4 (en) * 2003-09-19 2008-11-26 Otsuka Pharma Co Ltd HUMAN BETA DEFENSIN SECRETION AMPLIFIER
US20070256812A1 (en) * 2006-04-19 2007-11-08 Wen-Chen Wei Multidirectional heat dissipating structure
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
WO2014053592A1 (en) * 2012-10-03 2014-04-10 Proponent Biotech Gmbh Esters of short chains fatty acids for use in the treatment of immunogenic disorders

Also Published As

Publication number Publication date
MX2018013475A (es) 2019-08-12
WO2017198702A1 (en) 2017-11-23
BR112018072177A2 (pt) 2019-02-12
CN109152754A (zh) 2019-01-04
JP2019516797A (ja) 2019-06-20
RU2018143564A3 (enExample) 2020-07-23
RU2018143564A (ru) 2020-06-17
SG11201808322PA (en) 2018-10-30
CA3020485A1 (en) 2017-11-23
CL2018003270A1 (es) 2019-02-22
SG10202006016QA (en) 2020-07-29
KR20190009294A (ko) 2019-01-28
AU2017266726A1 (en) 2018-10-11
US20200000751A1 (en) 2020-01-02
JP6975473B2 (ja) 2021-12-01
EP3458043A1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
JP7621220B2 (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
ES2263643T3 (es) Uso de hidroxietilrutosidos para el tratamiento de los sintomas del r esfriado comun, de la fiebre de heno y de infecciones relacionadas con el tacto respiratorio.
KR102430892B1 (ko) 비강 울혈을 치료/예방하기 위한 카르복실산
EA008165B1 (ru) Композиции для лечения простуды
US9861647B2 (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
US20180125931A1 (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
KR102733397B1 (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
JP2019516797A5 (enExample)
CA2701388C (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
HK40002357A (en) Carboxylic acid for treating/preventing nasal congestion
KR20160127712A (ko) 다제내성 결핵 치료를 위한 흡입 에어로졸 면역화학요법
CN112074291A (zh) 预防和治疗呼吸道疾病的组合物
US20230072392A1 (en) Nasal spray
US20100311691A1 (en) Compositions of s-alkylisothiouronium derivatives for treating upper respiratory congestion
US20060210482A1 (en) Chemical composition and method for cold and sinus relief
US20170202835A1 (en) Osmolyte-containing preparation for the treatment of dry mucous membranes
WO2025146443A1 (en) Antibacterial compositions comprising honey
HK40121592A (en) Intranasal epinephrine formulations and methods for the treatment of disease
LV13113B (en) Ambroxol for the treatment of inflammation in the pharynx

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4